ICoN-1

Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Study Name:
Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Targeted Disease(s):
Other

Purpose of Study:

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)

Study Dates:
September 11, 2024 - December 1, 2028

Study Location:
Nationwide

Funding Source:
Mannkind Corporation

ClinicalTrails.gov Identifier:
NCT06418711

Register for Trial
Freedom From Smoking Clinic - Vancouver, WA
Vancouver, WA | Jan 01, 2025
Freedom From Smoking Clinic - Burlington, MA
Burlington, MA | Feb 24, 2025